ArticleJournal of pharmacokinetics and biopharmaceutics1995
In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery.
Article in Journal of pharmacokinetics and biopharmaceutics, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 32 citations in OpenAlex.
- Glucocorticoids-based prodrug design: Current strategies and research progress.Asian journal of pharmaceutical sciences · 2024Review
- Preparation and properties of BSA-loaded microspheres based on multi-(amino acid) copolymer for protein delivery.International journal of nanomedicine · 2014Article
- Production optimization of cyanophycinase ChpEal from Pseudomonas alcaligenes DIP1.AMB Express · 2011Article
- Polymer micelles with hydrazone-ester dual linkers for tunable release of dexamethasone.Pharmaceutical research · 2011Article
- Biotechnological process for production of beta-dipeptides from cyanophycin on a technical scale and its optimization.Applied and environmental microbiology · 2009Article
- In vitro and in vivo evaluation of microparticulate drug delivery systems composed of macromolecular prodrugs.Molecules (Basel, Switzerland) · 2008Review
- Engineered cyanophycin synthetase (CphA) from Nostoc ellipsosporum confers enhanced CphA activity and cyanophycin accumulation to Escherichia coli.Applied and environmental microbiology · 2006Article
- Engineering the genotype of Acinetobacter sp. strain ADP1 to enhance biosynthesis of cyanophycin.Applied and environmental microbiology · 2006Article
- Protamylasse, a residual compound of industrial starch production, provides a suitable medium for large-scale cyanophycin production.Applied and environmental microbiology · 2005Article
- Colonic drug delivery: prodrug approach.Pharmaceutical research · 2001Review
- ["Targeted delivery" in the gastrointestinal tract].Medizinische Klinik (Munich, Germany : 1983) · 1999Review
- In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery.Journal of pharmacokinetics and biopharmaceutics · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Glucocorticoids remain one of the mainstays of therapy for acute attacks of inflammatory bowel disease despite systemic side effects that limit their use. Prodrugs that selectively deliver glucocorticoids to the colon may lower the required dose and side effects. Because enzymes of gut microflora are able to cleave certain peptide and ester bonds, the ability of an ester prodrug consisting of dexamethasone (DX) as model drug and poly(L-aspartic acid) (weight-average mol wt = 30,000) as drug carrier was investigated to selectively release the drug in the large intestine. Prodrug and drug solutions (1.18 mg DX/ml DMSO) were administered to two groups of male Sprague-Dawley rats by intragastric infusion using an ALZET osmotic pump. All rats were infused for sufficient time to achieve steady state in both blood and GI-tract tissues. DX concentrations in blood and tissue samples were measured with HPLC. The steady state DX concentrations at these sites were used to calculate a drug delivery index (DDI). DX blood concentrations were significantly lower (p < 0.05) after intragastric administration of the prodrug. Moreover, prodrug administration resulted in significantly higher DX concentrations in the cecum and colon mucosa and the cecum muscle tissue compared to DX administration (p < 0.05). The prodrug led to an increase of the DX concentration in the large intestinal tissues by factors of 1.3-2.0 and to an 1.3-fold decrease of DX blood concentrations. Thus, this novel conjugate should both increase efficacy and reduce toxicity to some extent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.